JP2019515952A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515952A5 JP2019515952A5 JP2019505346A JP2019505346A JP2019515952A5 JP 2019515952 A5 JP2019515952 A5 JP 2019515952A5 JP 2019505346 A JP2019505346 A JP 2019505346A JP 2019505346 A JP2019505346 A JP 2019505346A JP 2019515952 A5 JP2019515952 A5 JP 2019515952A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- compound
- ring
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 73
- 229910052739 hydrogen Inorganic materials 0.000 claims description 61
- 229910052799 carbon Inorganic materials 0.000 claims description 46
- 239000001257 hydrogen Substances 0.000 claims description 32
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 28
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000005842 heteroatom Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000004429 atom Chemical group 0.000 claims description 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000001960 7 membered carbocyclic group Chemical group 0.000 claims description 2
- 125000003627 8 membered carbocyclic group Chemical group 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims description 2
- 238000000034 method Methods 0.000 description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 36
- 125000000217 alkyl group Chemical group 0.000 description 32
- 201000010099 disease Diseases 0.000 description 18
- 208000035475 disorder Diseases 0.000 description 18
- 239000000203 mixture Substances 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 9
- 201000011510 cancer Diseases 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 0 CCC*12*(C)C1CC*2 Chemical compound CCC*12*(C)C1CC*2 0.000 description 3
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000023178 Musculoskeletal disease Diseases 0.000 description 2
- 208000016222 Pancreatic disease Diseases 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- MCYRUVZWNZEEKE-UHFFFAOYSA-N CC(C)C(C)(C(C(C(C)C)=C1)NC(NS(c2cc(C#N)cc(C(C)(C)O)c2)(=O)=O)=O)C=C1C(OC)=O Chemical compound CC(C)C(C)(C(C(C(C)C)=C1)NC(NS(c2cc(C#N)cc(C(C)(C)O)c2)(=O)=O)=O)C=C1C(OC)=O MCYRUVZWNZEEKE-UHFFFAOYSA-N 0.000 description 1
- SILGEVPINXQJCF-UHFFFAOYSA-N CC(C)c1cc(C(N)=O)cc(C(C)=C)c1NC(NS(c1cc(C#N)cc(C(C)(C)O)c1)(=O)=O)=O Chemical compound CC(C)c1cc(C(N)=O)cc(C(C)=C)c1NC(NS(c1cc(C#N)cc(C(C)(C)O)c1)(=O)=O)=O SILGEVPINXQJCF-UHFFFAOYSA-N 0.000 description 1
- LJYBNNKRXKRIRH-UHFFFAOYSA-N CC(C)c1cc(F)cc(C(C)C)c1NC(NS(c1cc(C#N)cc(C(C)(C)O)c1)(=O)=O)O Chemical compound CC(C)c1cc(F)cc(C(C)C)c1NC(NS(c1cc(C#N)cc(C(C)(C)O)c1)(=O)=O)O LJYBNNKRXKRIRH-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007465 Giant cell arteritis Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 206010033649 Pancreatitis chronic Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000036923 autoimmune primary adrenal insufficiency Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000017445 musculoskeletal system disease Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 208000002865 osteopetrosis Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 206010043207 temporal arteritis Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324081P | 2016-04-18 | 2016-04-18 | |
| US201662324071P | 2016-04-18 | 2016-04-18 | |
| US62/324,071 | 2016-04-18 | ||
| US62/324,081 | 2016-04-18 | ||
| PCT/US2017/028166 WO2017184623A1 (en) | 2016-04-18 | 2017-04-18 | Compounds and compositions for treating conditions associated with nlrp activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019515952A JP2019515952A (ja) | 2019-06-13 |
| JP2019515952A5 true JP2019515952A5 (enExample) | 2020-05-28 |
| JP7050751B2 JP7050751B2 (ja) | 2022-04-08 |
Family
ID=58664792
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505347A Ceased JP2019518071A (ja) | 2016-04-18 | 2017-04-18 | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
| JP2019505346A Active JP7050751B2 (ja) | 2016-04-18 | 2017-04-18 | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019505347A Ceased JP2019518071A (ja) | 2016-04-18 | 2017-04-18 | Ｎｌｒｐ活性に関連する状態を処置するための化合物および組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11597706B2 (enExample) |
| EP (3) | EP3445756B1 (enExample) |
| JP (2) | JP2019518071A (enExample) |
| AU (2) | AU2017254523B2 (enExample) |
| ES (2) | ES2855732T3 (enExample) |
| MA (2) | MA56008A (enExample) |
| WO (2) | WO2017184623A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3046933B1 (fr) * | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| WO2017184623A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
| UA126675C2 (uk) | 2017-01-23 | 2023-01-11 | Дженентек, Інк. | Хімічні сполуки як інгібітори активності інтерлейкіну-1 |
| BR112019024831A2 (pt) | 2017-05-24 | 2020-06-09 | The University Of Queensland | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| PT3661925T (pt) | 2017-07-07 | 2022-01-31 | Inflazome Ltd | Novos compostos de sulfonamida-carboxamida |
| EP3658539B1 (en) | 2017-07-24 | 2024-02-21 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| JP7349981B2 (ja) * | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| WO2019034692A1 (en) * | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| JP2020531453A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤としてのスルホニルウレアおよびスルホニルチオウレア |
| WO2019034693A1 (en) | 2017-08-15 | 2019-02-21 | Inflazome Limited | SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| US12221434B2 (en) | 2017-11-09 | 2025-02-11 | Inflazome Limited | Sulfonamide carboxamide compounds |
| JP2021502364A (ja) * | 2017-11-09 | 2021-01-28 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| GB201803394D0 (en) * | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| WO2019166619A1 (en) | 2018-03-02 | 2019-09-06 | Inflazome Limited | Novel compounds |
| GB201803393D0 (en) * | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| US12168653B2 (en) | 2018-03-02 | 2024-12-17 | Inflazome Limited | Sulfonamide derivates as NLRP3 inhibitors |
| US11834433B2 (en) | 2018-03-02 | 2023-12-05 | Inflazome Limited | Compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| MA52489A (fr) | 2018-05-04 | 2021-03-10 | Inflazome Ltd | Nouveaux composés |
| US20220267276A1 (en) * | 2018-07-03 | 2022-08-25 | Novartis Ag | Nlrp modulators |
| CN113613721A (zh) * | 2018-07-03 | 2021-11-05 | 诺华股份有限公司 | Nlrp调节剂 |
| CN112654350A (zh) * | 2018-07-03 | 2021-04-13 | 诺华股份有限公司 | 使用nlrp3拮抗剂治疗对tnf抑制剂有抗性的受试者或针对所述患者选择治疗的方法 |
| WO2020018975A1 (en) | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| WO2020018970A1 (en) | 2018-07-20 | 2020-01-23 | Genentech, Inc. | Sulfonylurea compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| KR20210053910A (ko) | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| US20230011652A1 (en) * | 2018-10-24 | 2023-01-12 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| DK3880660T3 (da) * | 2018-11-13 | 2025-10-06 | Novartis Ag | Forbindelser og sammensætninger til behandling af tilstande forbundet med nlrp-aktivitet |
| WO2020102098A1 (en) * | 2018-11-13 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3880666B1 (en) | 2018-11-13 | 2023-06-28 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2020102574A1 (en) * | 2018-11-16 | 2020-05-22 | Novartis Inflammasome Research, Inc. | The compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) * | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| HRP20250104T1 (hr) | 2019-01-14 | 2025-03-28 | Zydus Lifesciences Limited | Novi supstituirani derivati sulfonilureje |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| CN111848461A (zh) * | 2019-04-29 | 2020-10-30 | 苏州大学 | Nlrp3炎症小体抑制剂及其制备方法和应用 |
| MX2021015561A (es) * | 2019-06-17 | 2022-01-24 | Olatec Therapeutics Llc | Composiciones farmaceuticas que contienen dapansutrilo. |
| US20220378801A1 (en) | 2019-06-21 | 2022-12-01 | Ac Immune Sa | Novel compounds |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| US12351564B2 (en) | 2019-07-17 | 2025-07-08 | Zomagen Biosciences Ltd | NLRP3 modulators |
| BR112022000878A2 (pt) * | 2019-07-17 | 2022-04-19 | Zomagen Biosciences Ltd | Derivados de n-((1,2,3,5,6,7-hexa-hidro-s-indacen-4-il)carbamoil)-4,5,6,7-tetra-hidrobenzofuran-2-sulfonamida e compostos relacionados como moduladores de nlpr3 para o tratamento de esclerose múltipla (ms) |
| JP2022545400A (ja) | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体 |
| WO2021043966A1 (en) | 2019-09-06 | 2021-03-11 | Inflazome Limited | Nlrp3 inhibitors |
| CN111100042B (zh) * | 2019-11-18 | 2022-05-31 | 苏州诚和医药化学有限公司 | 一种2-甲氧基-5-磺酰胺基苯甲酸的制备方法 |
| CN111018750B (zh) * | 2019-12-19 | 2022-05-27 | 苏州诚和医药化学有限公司 | 一种2,3-二甲氧基-5-磺酰胺基苯甲酸的制备新方法 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US20230121952A1 (en) | 2020-02-18 | 2023-04-20 | Inflazome Limited | Compounds |
| BR112022018480A2 (pt) * | 2020-03-16 | 2022-11-29 | Zomagen Biosciences Ltd | Moduladores de nlrp3 |
| WO2021185912A1 (en) | 2020-03-19 | 2021-09-23 | Softhale Nv | Method for the treatment nlrp3-associated diseases |
| JP7504234B2 (ja) * | 2020-06-11 | 2024-06-21 | シーセン ファーマシューティカル カンパニー リミテッド | ジメチルスルホキシミン誘導体 |
| MX2022014709A (es) | 2020-06-19 | 2022-12-16 | Ac Immune Sa | Derivados de dihidrooxazol y tiourea que modulan la ruta del inflamasoma de la proteina 3 que contiene el dominio pirina de la familia del receptor similar al dominio de oligomerizacion de union a nucleotido (nlrp3). |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| CN117279903A (zh) * | 2021-02-10 | 2023-12-22 | 杭州英创医药科技有限公司 | 作为nlrp3抑制剂的化合物 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| WO2022237780A1 (zh) * | 2021-05-10 | 2022-11-17 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN118355000A (zh) * | 2021-12-03 | 2024-07-16 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| JP2025502732A (ja) | 2021-12-22 | 2025-01-28 | エーシー・イミューン・エス・アー | ジヒドロオキサゾール誘導体化合物 |
| KR20250036233A (ko) | 2022-07-14 | 2025-03-13 | 에이씨 이뮨 에스에이 | Nlrp3 인플라마좀 경로의 조절제로서의 피롤로트리아진 및 이미다조트리아진 유도체 |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| US20240400571A1 (en) | 2023-06-02 | 2024-12-05 | Merck Sharp & Dohme Llc | 5,6 unsaturated bicyclic heterocyles useful as inhibitors of nod-like receptor protein 3 |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ238911A (en) * | 1990-07-17 | 1993-10-26 | Lilly Co Eli | Furyl, pyrrolyl and thienyl sulphonyl urea derivatives, pharmaceutical compositions and intermediates therefor |
| US5169860A (en) | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| CA2110524A1 (en) | 1992-12-10 | 1994-06-11 | Gerald Burr Grindey | Antitumor compositions and methods of treatment |
| AU723895B2 (en) * | 1997-01-29 | 2000-09-07 | Pfizer Inc. | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity |
| EP0987552A3 (en) | 1998-08-31 | 2000-06-07 | Pfizer Products Inc. | Diarylsulfonylurea binding proteins |
| EP1214087A1 (en) * | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| MXPA04002565A (es) * | 2001-11-30 | 2004-05-31 | Pfizer Prod Inc | Combinacion de un inhibidor de il-1/18 con un inhibidor de tnf para el tratamiento de inflamacion. |
| DK200600313A (da) * | 2006-03-03 | 2006-03-13 | Novo Nordisk As | Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor |
| CN105579433A (zh) * | 2013-05-21 | 2016-05-11 | 弗吉尼亚联邦大学 | 用于预防和治疗炎症的Cryopyrin抑制剂 |
| PE20221627A1 (es) | 2015-02-16 | 2022-10-19 | Univ Queensland | Sulfonilureas y compuestos relacionados y uso de estos |
| WO2017184623A1 (en) | 2016-04-18 | 2017-10-26 | Ifm Therapeutics, Inc | Compounds and compositions for treating conditions associated with nlrp activity |
-
2017
- 2017-04-18 WO PCT/US2017/028166 patent/WO2017184623A1/en not_active Ceased
- 2017-04-18 EP EP17722216.3A patent/EP3445756B1/en active Active
- 2017-04-18 EP EP17720928.5A patent/EP3445757B1/en active Active
- 2017-04-18 US US16/094,491 patent/US11597706B2/en active Active
- 2017-04-18 WO PCT/US2017/028167 patent/WO2017184624A1/en not_active Ceased
- 2017-04-18 US US16/094,499 patent/US11339136B2/en active Active
- 2017-04-18 ES ES17720928T patent/ES2855732T3/es active Active
- 2017-04-18 JP JP2019505347A patent/JP2019518071A/ja not_active Ceased
- 2017-04-18 EP EP20208882.9A patent/EP3872070A1/en not_active Withdrawn
- 2017-04-18 MA MA056008A patent/MA56008A/fr unknown
- 2017-04-18 ES ES17722216T patent/ES2927777T3/es active Active
- 2017-04-18 AU AU2017254523A patent/AU2017254523B2/en not_active Ceased
- 2017-04-18 AU AU2017254522A patent/AU2017254522B2/en not_active Ceased
- 2017-04-18 JP JP2019505346A patent/JP7050751B2/ja active Active
- 2017-04-18 MA MA044729A patent/MA44729A/fr unknown
-
2022
- 2022-04-01 US US17/711,205 patent/US11760735B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515952A5 (enExample) | ||
| JP2019518071A5 (enExample) | ||
| JP2020537657A5 (enExample) | ||
| JP2019519598A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| HRP20240521T1 (hr) | Spojevi i pripravci za liječenje stanja povezanih s aktivnošću nlrp | |
| JP2014515346A5 (enExample) | ||
| JPWO2020102096A5 (enExample) | ||
| JP2014037426A5 (enExample) | ||
| JP2019518766A5 (enExample) | ||
| JP2012507566A5 (enExample) | ||
| JP7328323B2 (ja) | ＳＭＡＲＣＡ２／ＢＲＭ ＡＴＰａｓｅ阻害剤としての尿素化合物及び組成物 | |
| JP2012532112A5 (enExample) | ||
| JP2018534348A5 (enExample) | ||
| CA2972014A1 (en) | Fused pyrimidine compounds for the treatment of hiv | |
| JP2017500334A5 (enExample) | ||
| UA129653C2 (uk) | Макроциклічна сполука як агоніст sting, спосіб з її застосуванням і шлях її застосування | |
| RU2014110623A (ru) | Пирролопиразиновые ингибиторы киназы | |
| JP2017505808A5 (enExample) | ||
| JP2010540508A5 (enExample) | ||
| JP2017501234A5 (enExample) | ||
| JP2012522759A5 (enExample) | ||
| JPWO2020086732A5 (enExample) | ||
| JP2010528021A5 (enExample) | ||
| JP2020504716A5 (enExample) |